iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorComputer and Technology
Current SymbolNASDAQ:ICAD
Previous Symbol
CUSIPN/A
Phone603-882-5200
Debt
Debt-to-Equity Ratio0.49
Current Ratio1.39
Quick Ratio1.23
Price-To-Earnings
Trailing P/E Ratio-6.64
Forward P/E Ratio-9.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.10 million
Price / Sales2.42
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.86 per share
Price / Book4.71
Profitability
EPS (Most Recent Fiscal Year)($0.61)
Net Income$-14,250,000.00
Net Margins-37.29%
Return on Equity-64.08%
Return on Assets-25.38%
Miscellaneous
Employees119
Outstanding Shares16,770,000
Market Cap$64.91 million
OptionableOptionable
iCAD (NASDAQ:ICAD) Frequently Asked Questions
What is iCAD's stock symbol?
iCAD trades on the NASDAQ under the ticker symbol "ICAD."
How were iCAD's earnings last quarter?
iCAD Inc (NASDAQ:ICAD) released its quarterly earnings data on Tuesday, November, 13th. The technology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The technology company had revenue of $6.19 million for the quarter, compared to analysts' expectations of $6.34 million. iCAD had a negative net margin of 37.29% and a negative return on equity of 64.08%. View iCAD's Earnings History.
When is iCAD's next earnings date?
Has iCAD been receiving favorable news coverage?
Media coverage about ICAD stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. iCAD earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of iCAD's key competitors?
Some companies that are related to iCAD include Pulse Biosciences (PLSE), T2 Biosystems (TTOO), RenovaCare (RCAR), RA Medical Systems (RMED), Alphatec (ATEC), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Endologix (ELGX), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Pro-Dex (PDEX), CAS Medical Systems (CASM), Repro-Med Systems (REPR) and Motus GI (MOTS).
Who are iCAD's key executives?
iCAD's management team includes the folowing people:
- Mr. Kenneth M. Ferry, CEO & Director (Age 64)
- Mr. Richard C. Christopher, Exec. VP, CFO, Treasurer & Sec. (Age 48)
- Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 50)
- Ms. Annette L. Heroux, VP of Admin. (Age 61)
- Mr. Jonathan Go, Sr. VP of R&D (Age 55)
Who are iCAD's major shareholders?
Which major investors are buying iCAD stock?
How do I buy shares of iCAD?
Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iCAD's stock price today?
One share of ICAD stock can currently be purchased for approximately $4.00.
How big of a company is iCAD?
iCAD has a market capitalization of $64.91 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe.
What is iCAD's official website?
How can I contact iCAD?
iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]
MarketBeat Community Rating for iCAD (NASDAQ ICAD)
MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
